HGH Fragment 176-191 is the last sixteen amino acids at the carboxyl end of the 191-residue human growth hormone molecule, isolated in Monash University work during the 1990s on the premise that the hormone's fat-mobilizing signal sits in that C-terminal region and can be separated from its growth-promoting activity. The honest bottom line is that the premise held in rodents and did not carry into people: the developed analogue AOD-9604 reached placebo-controlled human obesity trials, was generally well tolerated, and did not produce the weight loss the animal data had suggested. Neither molecule is FDA-approved for any indication, and the material circulating today moves almost entirely through research chemical suppliers under not-for-human-consumption labeling.
HGH Fragment 176-191 holds no FDA-approved indication in the United States, and the only placebo-controlled human obesity trials in this molecule family were run on the modified analogue AOD-9604, which was tolerated but showed no clinically meaningful weight loss advantage over placebo.
The relationship is closer to a paragraph torn from a book than to a smaller edition of it. Growth hormone is a single 191-amino-acid chain folded into a four-helix bundle, while the fragment reproduces only residues 176 through 191 and, by design, lacks the domains required to engage the growth hormone receptor. Marketing copy that calls the fragment a form of growth hormone inverts the point, since that stretch was singled out precisely because it does not behave like the hormone.
| Criteria | Recombinant human growth hormone | HGH Fragment 176-191 |
|---|---|---|
| Size | 191 amino acids, four-helix bundle | 16 amino acids, C-terminal stretch |
| GH receptor binding | Yes, driving hepatic IGF-1 release | Not expected, required domains absent |
| US regulatory status | Approved prescription drug with defined indications | No approved indication |
| Manufacturing standard | Pharmaceutical controls, prescribed with monitoring | Research chemical channel, no oversight |
Because HGH Fragment 176-191 lacks the domains needed to engage the growth hormone receptor, the published rationale holds that it neither raises IGF-1 nor builds lean tissue the way the intact 191-amino-acid hormone does, and it also cannot deliver any benefit that runs through that receptor.
The proposed mechanism is lipolysis, the hydrolysis of stored triglyceride into free fatty acids and glycerol, which preclinical work on the growth hormone C-terminal region reported as increased fat mobilization alongside reduced lipogenesis. Rodent literature points to beta-3 adrenergic signaling as the route, and that is where most of the skepticism sits, because the beta-3 receptor is a long-running graveyard for obesity drug candidates whose rodent results did not reappear in human fat tissue.
The lipolytic effect attributed to the growth hormone C-terminal fragment rests on rodent data implicating beta-3 adrenergic signaling, a pathway that has repeatedly failed to reproduce rodent-scale fat loss in human trials.
The evidence splits into two halves that tell opposite stories, and the popular account quotes only the first one. Rodent work on the C-terminal region reported reduced body fat and increased fat oxidation without the growth or glucose effects of the intact hormone, while the human program that followed was run on AOD-9604 rather than the raw sixteen-residue peptide and did not reach a clinically meaningful weight loss endpoint.
The fat-loss case for the growth hormone C-terminal fragment rests on rodent studies, while the only placebo-controlled human program in this family, run on AOD-9604 rather than the fragment itself, produced tolerability without a clinically meaningful weight loss advantage and was never carried to approval.
No version of this peptide is an approved drug in the United States, and each route that could have made it a legitimate product has been closed in turn. What remains is the research chemical channel, where not-for-human-consumption labeling is a seller's liability posture rather than any form of clearance, and where no regulator has evaluated the product at all.
HGH Fragment 176-191 has no FDA-approved indication, its analogue AOD-9604 was rejected as a new dietary ingredient and placed among the significant-safety-risk bulk substances reviewed under section 503A, and growth hormone fragments are prohibited at all times under the World Anti-Doping Agency's peptide hormones and growth factors category.
Almost every published detail about administration comes from the analogue program rather than from the vials sold as the fragment. Short peptides are broken down rapidly by digestive enzymes and absorbed poorly across the gut wall, which is why this class is ordinarily injected and why the AOD-9604 developers built a separate oral formulation to work around it. No established human dosing regimen exists for the fragment, because no approved human use exists to establish one for.
No established human dosing regimen exists for HGH Fragment 176-191, and the microgram-per-day protocols circulating on vendor sites and forums are user convention rather than trial-derived, describing a different molecule than the one studied in the AOD-9604 program.
The safety record is reassuring across a narrow slice and blank everywhere outside it. Controlled work on AOD-9604 reported adverse events at rates broadly comparable to placebo and, consistent with the molecule not engaging the growth hormone receptor, without the deterioration in glucose handling and insulin sensitivity that can accompany growth hormone administration. Tolerability across twelve to twenty-four weeks in a few hundred supervised participants is not a safety finding for years of unsupervised use, and it says nothing about the material actually being sold.
The tolerability data for this molecule family comes from a few hundred supervised participants studied over roughly twelve to twenty-four weeks on AOD-9604, which characterizes neither years of unsupervised use nor the unregulated material sold as HGH Fragment 176-191.
Vendor pages and article summaries routinely present the two names as synonyms, and that substitution is the single most common error in how this compound is discussed. AOD-9604 takes a slightly shorter version of the C-terminal region and adds a tyrosine residue at the amino terminus, a modification made during development at Metabolic Pharmaceuticals in Australia to improve the molecule's properties as a drug candidate. Regulators treat modified analogues as distinct entities, because a change of even one residue can alter stability, receptor interaction, clearance, and immunogenicity.
| Criteria | HGH Fragment 176-191 | AOD-9604 |
|---|---|---|
| Structure | Unmodified residues 176-191 | Shorter C-terminal segment plus an N-terminal tyrosine |
| Development path | None | Preclinical development, investigational new drug pathway, human trials |
| Controlled human data | Essentially none | Placebo-controlled Phase 2 in overweight and obese adults |
| Regulatory identity | Distinct entity, no filings | Distinct entity, NDI objection and 503A flag |
The human tolerability data routinely cited for HGH Fragment 176-191 was generated on AOD-9604, a structurally different analogue carrying an added tyrosine residue, so a claim resting on that data does not transfer to the unmodified fragment in the vial.
Product risk and molecule risk are separate problems here, and for anyone holding a vial the product risk is usually the larger of the two. Independent testing of peptides purchased from online sellers without a prescription found products that did not match their labels, carrying only a small fraction of the stated active peptide along with endotoxin contamination, with every purchased vial assessed as a substandard or falsified product.
Independent testing of peptides purchased online without a prescription assessed every purchased vial as a substandard or falsified product, with label mismatches, only a small fraction of the stated peptide content, and endotoxin contamination in material sold for injection.
Set beside what medicine can currently document, the fragment compares poorly, and the gap is one of evidence rather than of theory. Approved incretin-based medications, including GLP-1 receptor agonists and dual agonists, have been evaluated in large randomized, placebo-controlled trials with tens of thousands of participants, showing substantial and sustained weight reduction alongside cardiovascular and metabolic outcome data under regulatory review and post-market surveillance. Behavioral foundations have not been displaced either, since nutrition quality, protein adequacy, resistance training, sleep, and alcohol intake continue to determine how much of any weight change is fat rather than lean mass.
| Criteria | Approved incretin-based medications | HGH Fragment 176-191 |
|---|---|---|
| Trial scale | Randomized trials enrolling tens of thousands | No controlled human trial of the fragment |
| Weight outcome | Substantial, sustained reduction demonstrated | Undemonstrated, analogue trial null on studied endpoints |
| Oversight | FDA approval plus post-market surveillance | None, research chemical channel only |
Approved incretin-based weight-management drugs carry randomized outcome evidence in tens of thousands of participants while HGH Fragment 176-191 carries no controlled human trial at all, which is the difference between a demonstrated effect and an undemonstrated one.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
